Copyright: ©Author(s) 2026.
World J Stem Cells. Jul 26, 2026; 18(7): 122048
Published online Jul 26, 2026. doi: 10.4252/wjsc.122048
Published online Jul 26, 2026. doi: 10.4252/wjsc.122048
Table 1 Characteristics of included studies in the current review
| Ref. | Review type | Number of included studies | Total sample size | Intervention | Disease type | Outcome |
| Cheng et al[41], 2025 | SR-MA | 6 RCTs | 374 | MSC | Fistulizing Crohn’s disease | Clin/rad healing, AEs |
| Wang et al[53], 2024 | SR-MA | 7 RCTs, 3 observational studies | 1049 | MSC | Perianal fistulas | PDAI, clin/rad healing, AEs |
| Serrano-Fernandez et al[40], 2024 | SR-MA | 2 RCTs, 7 nRCTs, 2 observational studies | 280 | HSC | Fistulizing Crohn’s disease | Clin/rad healing |
| Ciccocioppo et al[52], 2019 | SR-MA | 6 RCTs, 10 nRCTs, 7 observational studies | 696 | MSC | Perianal fistulas | Clinical remission, AEs, cumulative incidence of safety and efficacy |
| Vuyyuru et al[39], 2024 | SR-MA | 2 RCTs | 233 | MSC | Fistulizing Crohn’s disease | Clinical remission, clinical response, AEs |
| Fousekis et al[38], 2024 | SR | 2 RCTs, 7 observational studies | 420 | Darvadstrocel | Fistulizing Crohn’s disease | AEs |
| Wang et al[51], 2023 | SR-MA | 10 RCTs | 487 | MSC | Perianal fistulas | Clin/rad healing |
| Zou et al[50], 2025 | SR-MA | 8 RCTs | 1056 | MSC | Perianal fistulas | Clin/rad. Healing |
| Emile et al[49], 2025 | SR-MA | 10 RCTs, 33 observational studies | 1160 | MSC | Perianal fistulas | Clinical remission, AEs, cumulative incidence of safety and efficacy |
| Cao et al[37], 2017 | SR-MA | 5 RCTs, 9 nRCTs | 469 | MSC | Fistulizing Crohn’s disease | Clinical remission, cumulative incidence of safety and efficacy |
| Cao et al[6], 2021 | SR-MA | 12 RCTs, 17 observational studies | 1252 | MSC | Fistulizing Crohn’s disease | Clinical remission, AEs, cumulative incidence of safety and efficacy |
| Guillo et al[36], 2025 | SR-MA | 4 RCTs, 20 nRCTs | 596 | MSC | Fistulizing Crohn’s disease | Combined remission, cumulative incidence of safety and efficacy |
| Cheng et al[32], 2019 | SR-MA | 7 RCTs | 530 | MSC | Perianal fistulas | Combined remission, AEs, clin/rad healing |
| Taxonera et al[35], 2025 | SR-MA | 7 full-text articles, 5 conference proceedings | 595 | Darvadstrocel | Fistulizing Crohn’s disease | Cumulative incidence of safety and efficacy |
| Cheng et al[47], 2023 | SR-MA | 6 studies | 307 | MSC | Perianal fistulas | Combined remission, AEs, clin/rad healing |
| Lightner et al[34], 2018 | SR-MA | 3 RCTs | 243 | MSC | Fistulizing Crohn’s disease | Clinical remission, AEs |
| Lee et al[33], 2018 | SR-MA | 2 RCTs | 233 | MSC | Fistulizing Crohn’s disease | Clinical remission, clinical response |
| Choi et al[46], 2019 | SR-MA | 3 RCTs, 13 observational studies | 400 | MSC | Perianal fistulas | Clin/rad healing, cumulative incidence of safety and efficacy |
| Cheng et al[48], 2020 | SR-MA | 5 RCTs, 8 nRCTs | 618 | MSC | Fistulizing Crohn’s disease | Combined remission, AEs, clin/rad healing, cumulative incidence of safety and efficacy |
| Li et al[31], 2023 | SR-MA | 5 RCTs | 558 | MSC | Fistulizing Crohn’s disease | Clin/rad healing, AEs |
| Dave et al[30], 2015 | SR-MA | 1 RCTs, 1 case report, 10 observational studies | 107 | MSC | Fistulizing Crohn’s disease | Cumulative incidence of safety and efficacy |
| El-Nakeep et al[29], 2022 | SR-MA | 4 RCTs | 269 | MSC | Fistulizing Crohn’s disease | Clin/rad healing |
| Ko et al[28], 2021 | SR | 32 studies | 762 | MSC | Fistulizing Crohn’s disease | AEs, healing |
| Ye et al[27], 2016 | SR | 6 HSC studies, 12 MSC studies | 493 | MSC, HSC | Fistulizing Crohn’s disease | AEs, healing |
| Narang et al[57], 2017 | SR | 1 RCTs, 3 observational studies | 270 | MSC, PRP | Cryptoglandular fistula | AEs, healing |
| Qiu et al[26], 2017 | SR-MA | 6 RCTs, 15 observational studies | 597 | MSC, HSC | Fistulizing Crohn’s disease | Clin/rad healing, cumulative incidence of safety and efficacy |
| Qiu et al[25], 2024 | SR-MA | 12 RCTs | 632 | MSC | Fistulizing Crohn’s disease | Clin/rad healing |
| Cheng et al[45], 2025 | SR-MA | 3 nRCTs | 74 | MSC exosomes | Perianal fistulas | Cumulative incidence of safety and efficacy |
| Elsamna et al[56], 2026 | SR-MA | 5 RCTs | 164 | PRP | Cleft palate repair | Fistula occurrence |
| Mazzaro et al[24], 2024 | SR-MA | 10 studies | 138 | PRP | Fistulizing Crohn’s disease | Cumulative incidence of safety and efficacy |
| Adamska et al[55], 2024 | SR | 7 studies | 164 | PRP | Oroantral communication and fistulas | Combined remission |
| Xu et al[44], 2024 | SR-MA | 4 RCTs, 15 observational studies | 418 | PRP | Perianal fistulas | Clin/rad healing, cumulative incidence of safety and efficacy |
| Mardiyan Kurniawati et al[54], 2023 | SR | 2 RCTs, 4 case reports, 9 observational studies | 600 | PRP | Vesicovaginal fistula | AEs, healing |
| Wang et al[43], 2023 | SR-MA | 5 RCTs, 7 case reports, 2 observational studies | 514 | PRP | Perianal fistulas | Clin/rad healing, cumulative incidence of safety and efficacy |
| Luo et al[42], 2022 | SR-MA | 3 RCTs, 6 observational studies | 289 | PRP | Perianal fistulas | Clin/rad healing, cumulative incidence of safety and efficacy |
- Citation: Duan YL, Wen YH, Chen SA, Nie R, Pang MQ, Deng MJ, Wang ZX, Fan HN. Efficacy and safety of cell-based regenerative therapies for fistula-related diseases: An umbrella review of systematic reviews. World J Stem Cells 2026; 18(7): 122048
- URL: https://www.wjgnet.com/1948-0210/full/v18/i7/122048.htm
- DOI: https://dx.doi.org/10.4252/wjsc.122048